Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.

Wang JA, Chen WA, Wang Y, Zhang S, Bi H, Hong B, Luo Y, Daugherty A, Xie X.

Atherosclerosis. 2011 Jul;217(1):90-6. doi: 10.1016/j.atherosclerosis.2011.03.005.

PMID:
21481872
2.

Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation.

Takahashi K, Matsumoto Y, Do e Z, Kanazawa M, Satoh K, Shimizu T, Sato A, Fukumoto Y, Shimokawa H.

PLoS One. 2013 Aug 13;8(8):e72558. doi: 10.1371/journal.pone.0072558.

3.

Chinese red yeast rice attenuates the development of angiotensin II-induced abdominal aortic aneurysm and atherosclerosis.

Xie X, Wang Y, Zhang S, Zhang G, Xu Y, Bi H, Daugherty A, Wang JA.

J Nutr Biochem. 2012 Jun;23(6):549-56. doi: 10.1016/j.jnutbio.2011.02.011.

PMID:
21764282
4.

Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.

Yang LX, Heng XH, Guo RW, Si YK, Qi F, Zhou XB.

J Cardiovasc Pharmacol. 2013 Aug;62(2):205-11. doi: 10.1097/FJC.0b013e3182967fc0.

PMID:
23615158
5.
6.

Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.

Li G, Wu XW, Lu WH, Ai R, Chen F, Tang ZZ.

BMC Cardiovasc Disord. 2014 Oct 18;14:145. doi: 10.1186/1471-2261-14-145.

7.

[Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].

Luo RN, Tao LJ, Zhou J, Wang R, Lu MM, Fu X.

Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Aug;39(8):743-8. Chinese.

PMID:
22169423
8.

Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I.

Li Y, Wang Q, Zhou J, Xu Q, Chu X, Sun T, Liu X, Cai S.

Eur J Pharmacol. 2014 Jan 15;723:23-8. doi: 10.1016/j.ejphar.2013.11.037.

PMID:
24333476
9.

Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice.

Uchida HA, Kristo F, Rateri DL, Lu H, Charnigo R, Cassis LA, Daugherty A.

Atherosclerosis. 2010 Aug;211(2):399-403. doi: 10.1016/j.atherosclerosis.2010.02.034.

10.

Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model.

Seto SW, Krishna SM, Moran CS, Liu D, Golledge J.

Clin Sci (Lond). 2014 Jul;127(2):123-34. doi: 10.1042/CS20130382.

PMID:
24476071
11.

Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.

Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K.

Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2246-53. doi: 10.1161/ATVBAHA.114.303715.

12.

Polychlorinated biphenyl 77 augments angiotensin II-induced atherosclerosis and abdominal aortic aneurysms in male apolipoprotein E deficient mice.

Arsenescu V, Arsenescu R, Parulkar M, Karounos M, Zhang X, Baker N, Cassis LA.

Toxicol Appl Pharmacol. 2011 Nov 15;257(1):148-54. doi: 10.1016/j.taap.2011.08.028.

13.
14.

Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.

Enomoto S, Sata M, Fukuda D, Nakamura K, Nagai R.

Biomed Pharmacother. 2009 Jan;63(1):19-26.

PMID:
18162361
15.

Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Subramanian V, Uchida HA, Ijaz T, Moorleghen JJ, Howatt DA, Balakrishnan A.

J Cardiovasc Pharmacol. 2012 Jan;59(1):66-76. doi: 10.1097/FJC.0b013e318235d5ea.

16.

Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice.

Liu J, Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Sorci-Thomas M, Cassis LA, Daugherty A.

Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1826-34. doi: 10.1161/ATVBAHA.115.305482.

17.

Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration.

Shiraya S, Miyake T, Aoki M, Yoshikazu F, Ohgi S, Nishimura M, Ogihara T, Morishita R.

Atherosclerosis. 2009 Jan;202(1):34-40. doi: 10.1016/j.atherosclerosis.2008.03.020.

PMID:
18482727
18.

Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.

Grothusen C, Bley S, Selle T, Luchtefeld M, Grote K, Tietge UJ, Drexler H, Schieffer B.

Atherosclerosis. 2005 Sep;182(1):57-69.

PMID:
16115475
19.

Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.

Monetti M, Canavesi M, Camera M, Parente R, Paoletti R, Tremoli E, Corsini A, Bellosta S.

Pharmacol Res. 2007 May;55(5):441-9.

PMID:
17350858
20.

Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.

Guo H, Shi Y, Liu L, Sun A, Xu F, Chi J.

Arch Med Res. 2009 Jul;40(5):345-51. doi: 10.1016/j.arcmed.2009.07.006.

PMID:
19766896
Items per page

Supplemental Content

Support Center